Browsing by Author "Valencia, Javier"

O conteúdo desse portal pode ser acessível em Libras usando o VLibras

Fale com a Fiocruz

Fundação Oswaldo Cruz

Now showing items 1-5 of 5

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

Takuva, Simbarashe et al. | Date Issued: 2022
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

Takuva, Simbarashe et al. | Date Issued: 2022
One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis

Swindells, Susan et al. | Date Issued: 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

Grinsztejn, Beatriz et al. | Date Issued: 2019
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial

Avihingsanon, Anchalee et al. | Date Issued: 2022

Conteúdo acessível em Libras usando o VLibras Widget com opções dos Avatares Ícaro, Hosana ou Guga.